Bedrosian Camille L: insider trades.
Bedrosian Camille L reported 5 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 2 sales ($325K), across 2 companies.
- Transactions
- 5
- Purchases (P)
- 0
- Sales (S)
- 2
- Companies
- 2
- Name as filed
- Bedrosian Camille L
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | Officer · Chief Medical Officer | 3 |
| Crinetics Pharmaceuticals, Inc. (CRNX) | Director | 2 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-10 | Amylyx Pharmaceuticals, Inc. | S | 7,947 | $32.21 | 280,145 | Form 4 |
| 2026-09-10 | Amylyx Pharmaceuticals, Inc. | S | 2,081 | $33.09 | 278,064 | Form 4 |
| 2026-09-01 | Crinetics Pharmaceuticals, Inc. | D | 16,300 | $85 | 5,925 | Form 4 |
| 2026-09-01 | Crinetics Pharmaceuticals, Inc. | D | 5,925 | $85 | 0 | Form 4 |
| 2026-08-18 | Amylyx Pharmaceuticals, Inc. | A | 22,807 | $0 | 288,092 | Form 4 |
Questions
What stock did Bedrosian Camille L buy or sell?
Bedrosian Camille L reported 5 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 2 sales ($325K), across 2 companies.
Is Bedrosian Camille L the same person as other filers with this name?
This page covers SEC CIK 1326969 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/bedrosian-camille-l-1326969.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.